Anticonvulsant prophylaxis for patients with brain tumours: Insights from clinical trials

Canadian Journal of Neurological Sciences

Volumn 30, Issue 2, 2003, Pages 89-90

  Mason, Warren P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CORTICOSTEROID; PHENYTOIN;

ANTICONVULSANT THERAPY; BRAIN TUMOR; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG USE; EDITORIAL; EPILEPSY; HUMAN; METASTASIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; SEIZURE; SEX DIFFERENCE; SIDE EFFECT; TUMOR GROWTH;

EID: 0037834583     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100053336     Document Type: Editorial

References (8)

1. Posner JB. Clinical manifestations of brain metastases. In: Gilbert HA, Posner JB, Weiss L, eds. Brain Metastases. Boston: GK Hall, 1980: 189-207.
2. Paillas JE, Pellet W. Brain metastases. In: Vinken PJ, Bruyn GW, eds. Handbook of Neurology. Amsterdam: North Holland 1975: 201-232.
3. Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981; 48: 384-394.
4. Forsyth PA, Weaver S, Fulton D, et al. Difficulties in answering an important question in neuro-oncology: prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003; 30: 106-112.
5. Glantz MJ, Cole BF, Friedberg MH, et al. A randomised, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumours. Neurology 1996; 46:985-991.
6. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 2000; 54: 1886-1893.
7. Bullard DE, Rawlings CE 3rd, Phillips B, et al. Oligodendroglioma: an analysis of the value of radiation therapy. Cancer 1987; 60: 2179-2188.
8. Byrne TN, Cascino TL, Posner JB. Brain metastases from melanoma. J Neuro-Onc 1983; 1: 313-317.